His primary scientific interests are in Pathology, Alzheimer's disease, Atrophy, Internal medicine and Magnetic resonance imaging. His research integrates issues of White matter, Grey matter, Multiple sclerosis and Brain mapping in his study of Pathology. His studies deal with areas such as Neuroimaging, Positron emission tomography, Dementia and Amyloidosis as well as Alzheimer's disease.
In his study, Disease is inextricably linked to Neuroscience, which falls within the broad field of Atrophy. His Internal medicine research is multidisciplinary, relying on both Oncology and Cardiology. His Magnetic resonance imaging research is multidisciplinary, incorporating perspectives in Cerebral cortex, Predictive value of tests, Cognitive test and Hazard ratio.
Stephen D. Weigand spends much of his time researching Pathology, Internal medicine, Alzheimer's disease, Dementia and Atrophy. The Pathology study which covers Magnetic resonance imaging that intersects with Predictive value of tests. His work carried out in the field of Internal medicine brings together such families of science as Endocrinology, Oncology and Cardiology.
He works mostly in the field of Alzheimer's disease, limiting it down to topics relating to Neuroimaging and, in certain cases, Cerebrospinal fluid. The Dementia study combines topics in areas such as Cohort study, Cognition, Pediatrics and Audiology. His Atrophy study deals with Temporal lobe intersecting with Posterior cingulate.
Stephen D. Weigand mainly focuses on Dementia, Internal medicine, Disease, Pathology and Atrophy. Stephen D. Weigand has researched Dementia in several fields, including Apolipoprotein E, Cognition and Pediatrics. His Internal medicine course of study focuses on Oncology and Cognitive impairment and Amyloidosis.
His biological study spans a wide range of topics, including Hippocampus and Entorhinal cortex. His study looks at the relationship between Alzheimer's disease and fields such as Biomarker, as well as how they intersect with chemical problems. In his research on the topic of Neurofibrillary tangle, Neuroscience is strongly related with Tauopathy.
His primary areas of investigation include Internal medicine, Magnetic resonance imaging, Entorhinal cortex, Dementia and Alzheimer's disease. His Internal medicine study often links to related topics such as Oncology. His studies examine the connections between Magnetic resonance imaging and genetics, as well as such issues in Positron emission tomography, with regards to Neuroimaging and Amyloid.
His Entorhinal cortex research incorporates themes from Standardized uptake value, Temporal lobe, Effects of sleep deprivation on cognitive performance and Pathology. His research in Pathology intersects with topics in Hippocampal sclerosis and Hippocampal formation. His work on Alzheimer's disease is being expanded to include thematically relevant topics such as Biomarker.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.
Clifford R Jack;David S Knopman;William J Jagust;Ronald C Petersen.
Lancet Neurology (2013)
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
Clifford R. Jack Jr.;Val J. Lowe;Stephen D Weigand;Heather J. Wiste.
Comparison of Different MRI Brain Atrophy Rate Measures with Clinical Disease Progression in AD
C. R. Jack;M. M. Shiung;J. L. Gunter;P. C. O'Brien.
Inflammatory Cortical Demyelination in Early Multiple Sclerosis
Claudia F. Lucchinetti;Bogdan F.G. Popescu;Reem F. Bunyan;Natalia M. Moll.
The New England Journal of Medicine (2011)
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
Clifford R. Jack;Val J. Lowe;Matthew L. Senjem;Stephen D. Weigand.
3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease
Jennifer L. Whitwell;Scott A. Przybelski;Stephen D. Weigand;David S. Knopman.
Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI
Clifford R. Jack;M. M. Shiung;S. D. Weigand;P. C. O'Brien.
Primary central nervous system vasculitis: analysis of 101 patients.
Carlo Salvarani;Robert D. Brown;Kenneth T. Calamia;Teresa J. H. Christianson.
Annals of Neurology (2007)
An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease
Clifford R. Jack;David S. Knopman;Stephen D. Weigand;Heather J. Wiste.
Annals of Neurology (2012)
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease
Clifford R. Jack;Heather J. Wiste;Prashanthi Vemuri;Stephen D. Weigand.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: